Health-related quality of life and tolerability in patients with/without skin toxicity during loncastuximab tesirine treatment in a phase 2 clinical trial (LOTIS-2)
Authors
Spira, A.Zhou, X. L.
Liao, L.
Yu, E.
Chen, L.
Lau, A.
Wang, Y.
Gnanasakthy, A.
Radford, John A
Hamadani, M.
Affiliation
Virginia Cancer Specialists Research Institute, Fairfax, USAIssue Date
2022